EMA Authorised: Benepali (etanercept) — Samsung Bioepis NL B.V.

View source ↗

Summary

The European Medicines Agency authorised Benepali (etanercept), a biosimilar to etanercept, for inflammatory conditions including rheumatoid arthritis, psoriati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• Benepali (etanercept)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Psoriatic;Arthritis, Rheumatoid;Psoriasis. MAH: Samsung Bioepis NL B.V.. Decision date: 01/12/2025